Cargando…

CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial

BACKGROUND: CA-125 as a tumour progression criterion in relapsing ovarian cancer (ROC) trials remains controversial. CALYPSO is a large randomised trial incorporating CA-125 (GCIG criteria) and symptomatic deterioration in addition to Response Evaluation Criteria in Solid Tumours (RECIST) criteria (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alexandre, J, Brown, C, Coeffic, D, Raban, N, Pfisterer, J, Mäenpää, J, Chalchal, H, Fitzharris, B, Volgger, B, Vergote, I, Pisano, C, Ferrero, A, Pujade-Lauraine, E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Clinical Studies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3322951/ https://www.ncbi.nlm.nih.gov/pubmed/22240800 http://dx.doi.org/10.1038/bjc.2011.593

Ejemplares similares

Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients
por: Wagner, U, et al.
Publicado: (2012)

Jestina's calypso & other plays
por: Lovelace, Earl, 1935-
Publicado: (1984)

Validation of the Calypso Surface Beacon Transponder
por: Belanger, Maxwell, et al.
Publicado: (2016)

Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer
por: Lee, C K, et al.
Publicado: (2011)

Analysis of the X-ray tomograph measurements of Calypso prototype
por: Bini, C, et al.
Publicado: (1997)

Measurement of the maximum drift time in the Calypso MDT Chamber
por: Bagnaia, P, et al.
Publicado: (1997)

Calypso's spell: accidental near‐fatal thiacloprid intoxication
por: Zuercher, Patrick, et al.
Publicado: (2017)

Implementation of the Calypso system: a commissioning experience
por: Prunaretty, Jessica, et al.
Publicado: (2023)

Mechanical and thermal tests on the BIL MDT chamber prototype "Calypso"
por: Daly, C, et al.
Publicado: (1997)

Prediction of tumour response induced by chemotherapy using modelling of CA-125 kinetics in recurrent ovarian cancer patients
por: Wilbaux, M, et al.
Publicado: (2014)

Calypso: a full-scale MDT prototype for the ATLAS muon spectrometer
por: Biscossa, A, et al.
Publicado: (1998)

Bevacizumab and oral metronomic cyclophosphamide in platinum-resistant ovarian cancer
por: Pujade-Lauraine, Eric
Publicado: (2013)

Dosimetric Evaluation of the QFix kVue(TM) Calypso Couch Top
por: Hou, Lingtong, et al.
Publicado: (2021)

A simple algorithm to assess patient suitability for Calypso‐seed implantation for four‐dimensional prostate localization
por: Kimple, Randall J., et al.
Publicado: (2009)

Calypso: a user-friendly web-server for mining and visualizing microbiome–environment interactions
por: Zakrzewski, Martha, et al.
Publicado: (2017)

Pollinator Behaviour on a Food-Deceptive Orchid Calypso bulbosa and Coflowering Species
por: Tuomi, Juha, et al.
Publicado: (2015)

Novel Wavelet-Based Segmentation of Prostate CBCT Images with Implanted Calypso Transponders
por: Liu, Yingxia, et al.
Publicado: (2017)

Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer
por: González Martín, Antonio, et al.
Publicado: (2019)

Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer
por: Ledermann, Jonathan A., et al.
Publicado: (2019)

Performance Evaluation of Calypso 4D Localization and Kilovoltage Image Guidance Systems for Interfraction Motion Management of Prostate Patients
por: Ogunleye, Tomi, et al.
Publicado: (2009)

Fertility-sparing treatment for intramucous, moderately differentiated, endometrioid endometrial cancer: a Gynecologic Cancer Inter-Group (GCIG) study
por: Falcone, Francesca, et al.
Publicado: (2020)

Lack of relationship between EGFR-1 immunohistochemical expression and prognosis in a multicentre clinical trial of 93 patients with advanced primary ovarian epithelial cancer (GINECO group)
por: Elie, C, et al.
Publicado: (2004)

Testbeam results from the Calypso MDT Chamber Rev. 24 Oct. 1997 : sent on 20-11-1997
por: Bagnaia, P, et al.
Publicado: (1997)

Results from the 1998 test beam of the Calypso chamber filled with an Ar-CO2 gas mixture.
por: Creti, P, et al.
Publicado: (1999)

Commissioning and quality assurance of Calypso four-dimensional target localization system in linear accelerator facility
por: Muralidhar, K. R., et al.
Publicado: (2013)

Migration of Calypso beacon transponders for hepatic stereotactic body radiotherapy: a report of two cases
por: Amjad, Razan, et al.
Publicado: (2022)

Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO
por: Ray-Coquard, I, et al.
Publicado: (2013)

Comments on: Fertility-sparing treatment for intramucous, moderately differentiated, endometrioid endometrial cancer: a Gynecologic Cancer Inter-Group (GCIG) study
por: Park, Jeong-Yeol
Publicado: (2020)

Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer—A Study of the GANNET53 Consortium
por: Ray-Coquard, Isabelle, et al.
Publicado: (2019)

Generation and verification of QFix kVue Calypso‐compatible couch top model for a dedicated stereotactic linear accelerator with FFF beams
por: Gardner, Stephen J., et al.
Publicado: (2015)

Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial
por: Stark, Dan, et al.
Publicado: (2013)

Oral exposure to thiacloprid-based pesticide (Calypso SC480) causes physical poisoning symptoms and impairs the cognitive abilities of bumble bees
por: Kaila, Lotta, et al.
Publicado: (2023)

The post-progression survival of patients with recurrent or persistent ovarian clear cell carcinoma: results from a randomized phase III study in JGOG3017/GCIG
por: Kondo, Eiji, et al.
Publicado: (2020)

Initial experience with intra‐fraction motion monitoring using Calypso guided volumetric modulated arc therapy for definitive prostate cancer treatment
por: Bell, Linda J., et al.
Publicado: (2017)

CA-125 Early Dynamics to Predict Overall Survival in Women with Newly Diagnosed Advanced Ovarian Cancer Based on Meta-Analysis Data
por: Karamouza, Eleni, et al.
Publicado: (2023)

Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial
por: Clamp, Andrew R, et al.
Publicado: (2019)

Side Effects from Cancer Therapies and Perspective of 1044 Long-Term Ovarian Cancer Survivors—Results of Expression VI–Carolin Meets HANNA–Holistic Analysis of Long-Term Survival with Ovarian Cancer: The International NOGGO, ENGOT, and GCIG Survey
por: Woopen, Hannah, et al.
Publicado: (2023)

Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial
por: Pujade-Lauraine, Eric, et al.
Publicado: (2023)

Do ultrathin strut bare-metal stents with passive coating improve efficacy in large coronary arteries? Insights from the randomized, multicenter BASKET-PROVE trials
por: Hansen, Kim Wadt, et al.
Publicado: (2019)

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial
por: Oza, Amit M, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_nsj6vp1h0i4k15l9ei2hp7850o